In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma.
The safety profile was excellent. The prolonged progression-free survival (PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial. Such finding suggests that a subset of patients with renal cell carcinma may particularly benefit from everolimus.
Written by:
Virtuoso A, Policastro T, Izzo M, Federico P, Buonerba C, Rescigno P, Di Lorenzo G. Are you the author?
Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi Federico II, 80131 Naples, Italy.
Reference: World J Clin Cases. 2013 Aug 16;1(5):166-8.
doi: 10.12998/wjcc.v1.i5.166
PubMed Abstract
PMID: 24303493
UroToday.com Renal Cancer Section
